# PortfolioAI — Gate H Closure Record

**Date:** 21 September 2026
**Repository:** `drddutta-portfolio/PortfiolioAI`
**Branch:** `r4n-pharma-subprofile-architecture`
**PR:** #101 — OPEN / DRAFT / UNMERGED
**Target:** TORNTPHARM / PHARMA_V1
**Status:** COMPLETE / PASS

## Closure declaration

Gate H is formally closed as:

```text
H1 = COMPLETE / PASS
H2 = COMPLETE / PASS
H3 = COMPLETE / PASS
H4 = COMPLETE / PASS

GATE H = COMPLETE
TORNTPHARM FIRST DETERMINISTIC SCORE = COMPLETE
```

The first deterministic TORNTPHARM PHARMA_V1 company score is:

> **75.1575 / 100**

Closure quality:

> **REPRODUCIBLE / HAND-VERIFIED / NON-PERSISTING**

## Final ten-dimension score

| Dimension | Score | Weight | Weighted contribution |
|---|---:|---:|---:|
| Quality | 92 | 13% | 11.9600 |
| Growth | 78.25 | 15% | 11.7375 |
| Capital Efficiency | 79 | 10% | 7.9000 |
| Cash Flow | 93.6 | 10% | 9.3600 |
| Balance Sheet / Credit | 65 | 10% | 6.5000 |
| Business Durability | 75 | 10% | 7.5000 |
| Valuation | 30 | 12% | 3.6000 |
| Momentum | 95 | 8% | 7.6000 |
| Ownership / Governance | 70 | 6% | 4.2000 |
| Risk | 80 | 6% | 4.8000 |
| **Total** | — | **100%** | **75.1575** |

No denominator renormalization is used.

## Overlay treatment

Global Generics:

- reviewed business exposure = Material;
- locked economic materiality = 12.05%;
- approved numeric-overlay threshold = 15%;
- numeric modifier = not applied / null;
- second independent stock score = none.

CDMO / CRAMS:

- Emerging Watch;
- numeric participation = none;
- denominator participation = none;
- second independent stock score = none.

## Governance and risk treatment

Current TORNTPHARM governance/regulatory runtime:

- state = CLEAR;
- historical Indrad event retained;
- preview block = NO;
- additional numeric penalty = NONE;
- overall score cap = NONE;
- second regulatory penalty = NO.

Historical G-FINAL-3 and H1 snapshots remain frozen at their earlier fail-closed states and were not rewritten by later H2 resolution.

## Independent H4 verification

H4 independently reconstructed all ten dimension scores from locked observations / reviewed component states and approved contracts.

Independent hand result:

> **75.1575 / 100**

H3 adapter result:

> **75.1575 / 100**

Result:

> **EXACT MATCH / DETERMINISM PASS**

H4 also verified:

- no BANK_NBFC methodology leakage;
- no NIFTY Bank benchmark leakage;
- NIFTY Pharma benchmark retained;
- no Global Generics second stock score;
- no CDMO Emerging numeric inclusion;
- no governance double counting;
- no missing-evidence neutralization;
- no hidden denominator renormalization;
- complete evidence lineage;
- complete methodology lineage.

## Final engineering validation

The owner reran:

```bash
git pull && bash scripts/h4-validate-torntpharm-gate-h-closure.sh
```

Final owner result:

> **ALL PASS**

The closure validation covered:

- focused H4 + Gate H regression tests;
- full non-Edge application Vitest suite;
- strict TypeScript;
- presentation data-boundary architecture guard;
- focused H4 lint;
- architecture lint;
- production build;
- `git diff --check`.

Edge tests were not required because H4 touched no Edge Function code. The project-wide Edge/Deno tests remain unchanged.

## Canonical stage records

- H2 closure: `docs/PortfolioAI_GATE_H_H2_CLOSURE.md`
- H3 score/closure: `docs/PortfolioAI_GATE_H_H3_FIRST_DETERMINISTIC_READ_ONLY_SCORE.md`
- H4 verification/closure: `docs/PortfolioAI_GATE_H_H4_FINAL_VERIFICATION_AND_CLOSURE.md`
- Gate H plan: `docs/PortfolioAI_GATE_H_TORNTPHARM_FIRST_DETERMINISTIC_SCORE_PLAN.md`
- cumulative handoff: `docs/PORTFOLIOAI_CUMULATIVE_DEVELOPMENT_HANDOFF.md`

## Safety state at closure

- official score persistence = OFF;
- recommendation = OFF;
- position sizing = OFF;
- production Supabase mutation = NO;
- provider call for H4 = NO;
- deployment = NO;
- PR #101 merge = NO;
- rollout to other Pharma stocks = NO.

## Next stage

Gate I is:

> **NOT STARTED**

Gate I may begin only by separate explicit owner instruction.

PR #101 remains open, draft, and unmerged.
